
News|Articles|October 3, 2026
8 Pulmonology Headlines You Missed in Q3 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Pulmonology has seen significant growth over the past few months, with the acceptance of major New Drug Applications by the
Related to this article

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Advertisement
Advertisement

